| Project/Area Number |
21591349
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
IMAI Chihaya 新潟大学, 医歯学総合病院, 講師 (90419284)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
IMAMURA Masaru 新潟大学, 医歯学総合病院, 特任助教 (80464006)
SAKIKO Yoshida 新潟大学, 医歯学総合病院, 特任助教 (30535183)
TAKACHI Takayuki 新潟大学, 医歯学総合病院, 医員 (70444164)
|
|---|
| Project Period (FY) |
2009 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | NK細胞 / chimeric receptor / 細胞療法 / 難治性白血病 / 臍帯血移植 / CD19 / 4-1BB / CD28 / キメラ型受容体 / B細胞性腫瘍 / CD4^+ T細胞 / CD4^+T細胞 |
|---|
| Research Abstract |
Genetic modification and ex vivo expansion of human natural killer cells were investigated in order to overcome cellular resistance of leukemia, with special interests in the following subjects: 1) feasibility and applicability of the method using the peripheral blood (PB) obtained from patients who suffer from relapse after cord blood transplantation (CBT), 2) improvement of the signal transduction of the anti-CD19 chimeric antigen receptors, 3) improvement of NK cell persistence after in vivo infusion. In this study, ex vivo expansion and genetic modification of donor-derived NK cells from the patients’ PB was shown to be feasible in CBT recipients. The donor-derived NK cells from the patients’ PB were able to expand ex vivo, were susceptible to retroviral gene transduction and exerted powerfulcytotoxicity against CD19^+ leukemia cells via anti-CD19-chimeric receptors.
|
